Heat anti-Parkinson’s Disease——Carbidopa and LevodopaCR Tablets the first domestic generic

Recently,China Drug Administration (CDA)publicised the SJZ NO.4 Pharmaceutical approval certificate delivery information, CarbidopaandLevodopaCRTablets approved for listing, deemed to pass the consistency evaluation, took the first generic of Sinemet which is the Merck’s original drug .

The patent of the original drug ——Sinemet has expired, but no similar drugs have been approved for listing in China before.

CarbidopaandLevodopaCRTablets, developed and manufactured by Merck Sharp & Dohme, is a 4:1 compound extended-release preparation of levodopa and carbidopa, mainly used for the treatment of primary Parkinson‘s disease, post-encephalitis Parkinson‘s syndrome and Parkinson‘s syndrome with vitamin preparations containing pyridoxine.The patent of the original  drug, Sinemet has expired, but no similar drug has been approved and marketed in China before. Due to reasons such as production links and intermediary channels, Sinemet was once out of stock in China, and the price of the drug soared from 50 RMB to 980 RMB in 2021, causing a great burden to patients. The approval of the first generic drug of SJZ NO.4 Pharmaceutical has provided patients with more choices of medication.

PD is a comprehensive disease involving multiple systems, and its drug development involves multiple targets.At present, the clinical use of PD therapeutic drugs or dopamine replacement therapy as the main line of symptomatic treatment, some dopaminergic drugs new dosage form and non-dopaminergic drugs have been listed in foreign countries or are in clinical trials.In addition to the traditional dopamine transporter system, cholinergic transporter system and 5-HT transporter system, the new use of old drugs targeting new mechanisms has become a shortcut to develop anti-PD drugs.

It is imperative for domestic enterprises to speed up the research and development of PD drugs, and in the process of drug research and development can not be avoided in the drug impurity control problems, SZEB has been committed to helping customers to solve the problem of efficiently, to provide a comprehensive solution for drug impurity control products. At the same time, the advantage of the supply of levodopa, carbidopa, opicapone, ambroxol, nilotinib and other drug impurity control/standard products,, more information on drug impurities, please go to the official website: www.ex-biotech.com. Welcome to contanct us by calling the phone: 0755--23051186 or mailing to services@ec-biotech.com.


Contents from：yaoZh.com